Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts

Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts

We aimed to validate the association of 28 GWAS-identified genetic variants for response to TNF inhibitors (TNFi) in a discovery cohort of 1361 rheumatoid arthritis (RA) patients monitored in routine care and ascertained through the REPAIR consortium and DANBIO registry. We genotyped selected marker...

Full description

Bibliographic Details
Main Authors: Jose Manuel Sánchez-Maldonado, Rafael Cáliz, Miguel Ángel López-Nevot, Antonio José Cabrera-Serrano, Ana Moñiz-Díez, Helena Canhão, Rob Ter Horst, Luca Quartuccio, Signe B. Sorensen, Bente Glintborg, Merete L. Hetland, Ileana Filipescu, Eva Pérez-Pampin, Pablo Conesa-Zamora, Jerzy Swierkot, Alfons A. den Broeder, Salvatore De Vita, Eva Rabing Brix Petersen, Yang Li, Miguel A. Ferrer, Alejandro Escudero, Mihai G. Netea, Marieke J. H. Coenen, Vibeke Andersen, João E. Fonseca, Manuel Jurado, Katarzyna Bogunia-Kubik, Eduardo Collantes, Juan Sainz
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Immunology
Subjects:
GWAS
genetic variant
rheumatoid arthritis
drug response
TNF inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.672255/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.672255/full

Similar Items